Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.
about
Role of NADPH oxidases in liver fibrosis.MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1.Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study.The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosisLosartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project.International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].Losartan may inhibit the progression of liver fibrosis in chronic HCV patients.Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis CThe role of the renin-angiotensin system in liver fibrosis.Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.Modulation of angiotensin II signaling in the prevention of fibrosis.Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis.Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment.Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1α in a rat model.Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse.Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.
P2860
Q33632736-42CDAA1E-9D44-4472-AEC4-784F0222165CQ33846263-9656A845-D425-4D45-92C0-6CF2C4C83B58Q33855738-57311A9B-FED1-4CF6-BFF6-75FD4E913771Q35150772-9882AAA2-0FB7-4304-A8E8-09DF369588A4Q35276739-B6EE004A-5DF3-426E-A6D7-E7DEA82D0018Q35744613-FD695A26-E99D-4515-AC3A-4484BA021B0AQ35931751-FEDE8585-CC47-4138-B4C8-E05059A1C3B8Q36206673-242B3EC0-38DA-48C1-BB51-CA4C36596F18Q36241932-26E10962-BB0A-4551-9D9B-32644D247E20Q36924883-A0C28A09-2C4D-4E5B-A65B-3D26FEEC33A3Q37192537-94887BA8-C767-49DE-B3D4-DAC2F56230A9Q37391823-EF09E350-6B0D-45B6-8E1C-C822C03FEF4EQ37867350-2AC6B143-28CC-4A6E-BB5A-10D117C0A2CEQ38006726-9BC8FFB5-2455-4519-BACA-D4E4093E9C15Q38212215-10C100BD-EEC3-49CF-BAA8-D33B7C36B79FQ40362636-BB920FA9-DFD2-44F7-8FA1-ED5683F79D27Q40743246-6B8752D0-082D-4B81-A60D-47B3484F848AQ41029212-06F1B435-FD38-4A5F-A226-A5C6587E5AE0Q42591676-7A27E95B-9185-4DA0-B0B7-75C7BD09A2AFQ42972424-159A1447-ACC7-46C1-82DC-4C059D93FA31Q45014583-E33892CC-CB53-4500-9563-4632BB781EDFQ46480839-9335E12A-1D90-4360-A3BC-248651D0D624Q54515938-CBB123EB-1387-4FB4-8B0D-A271B59978D8Q55008612-8E18A6C4-577D-4C6F-961D-62F765E39497Q55363090-B510FBDE-7317-43DF-9A01-D4CC5AF6BE35
P2860
Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effects of six months losartan ...... tis C patients: a pilot study.
@ast
Effects of six months losartan ...... tis C patients: a pilot study.
@en
type
label
Effects of six months losartan ...... tis C patients: a pilot study.
@ast
Effects of six months losartan ...... tis C patients: a pilot study.
@en
prefLabel
Effects of six months losartan ...... tis C patients: a pilot study.
@ast
Effects of six months losartan ...... tis C patients: a pilot study.
@en
P2093
P2860
P356
P1476
Effects of six months losartan ...... tis C patients: a pilot study.
@en
P2093
Gustavo Castaño
María Alejandra Fernández
Silvia Sookoian
P2860
P304
P356
10.3748/WJG.V11.I48.7560
P407
P577
2005-12-01T00:00:00Z